Clinical trials
Phase 3 Colorectal Neoplasms trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
44 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 2 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 5 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 22 |
| Recruiting | 10 |
| Terminated | 5 |
| Unknown status | 4 |
| Active, not recruiting | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 3 |
| Pfizer | 3 |
| Amgen | 2 |
| Bayer | 2 |
| Boehringer Ingelheim | 2 |
| Bristol-Myers Squibb | 2 |
| Egetis Therapeutics | 2 |
| Haruhiko Fukuda | 2 |
| Hokkaido Gastrointestinal Cancer Study Group | 2 |
| Janssen Research & Development, LLC | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colorectal Neoplasms | 44 |
| Colonic Neoplasms | 6 |
| Gastrointestinal Neoplasms | 6 |
| Digestive System Neoplasms | 5 |
| Intestinal Neoplasms | 5 |
| Neoplasms | 5 |
| Digestive System Diseases | 4 |
| Gastrointestinal Diseases | 4 |
| Neoplasm Metastasis | 4 |
| Colonic Diseases | 3 |
Trials
Showing 1 to 25 of 44. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.